As you can see from the program committee report, we should have a great showing at the 2009 meeting from this specialty section. Many thanks to all those who put in such an effort to submit such quality programs to SOT national. During the recent SOT meeting in Seattle, the SOT Endowment Fund steering committee made a proposal to all of the leaders of the Specialty Sections to promote them to make contributions to the Endowment Fund. They encouraged the Specialty Sections to create permanently restricted net asset funds. A total of $25,000 is required for such a fund, but currently, there are matching funds from the SOT.

During the ImTox SS reception, a number of representatives from the HESI Immunotoxicology Technical Committee (ITC) began a discussion centered around the possibility that the ITC could provide the necessary donation of $12,500. This donation would satisfy the minimum requirement established by the SOT Endowment Fund and would enable the creation of the $25,000 fund with the matching SOT dollars. The ‘offer’ for the matching contribution from the Endowment Funds is for a limited time. Once these funds are committed, then a donation of the full $25,000 will be required to create a permanently restricted net asset fund. The great news is that the HESI ITC will provide a total of $12,500, which will be donated to the SOT Endowment Fund on behalf of the ImTox SS to create the HESI ITC Immunotoxicology Young Investigator Travel Award Fund. I am currently working with the SOT Endowment Fund committee to get this established and soon you should see this on the list as one of the funds you can contribute to. The use of this fund will then be managed through the ImTox SS to help with travel awards to the annual meeting. Many thanks to all of those members on the ITC for their willing support of the ImTox SS.
In planning for success for next year’s meeting in Baltimore, please remember to recognize your colleagues and your students/post-docs by nominating them for the awards given out by this SS. Also, it’s not too soon to be thinking about proposals for sessions/CE courses for the 2010 meeting!

For the past three years, the officers of the Regional Chapters, Specialty Sections, and Special Interest Groups have convened in the summer to enhance networking, discuss ideas that could be initiated by these groups, or to express concerns that might be addressed by the National SOT. Representatives of these organizations (usually the President, Vice President or Vice President-elect) found these gatherings to be quite useful and hopefully this year will not be an exception. For the 2008 Leadership Meeting, SOT is planning a new approach. Rather than each group meeting separately, they have arranged to bring all the officers together to hear from SOT Council and staff liaisons and to engage in breakout sessions (2-3) to discuss issues of particular interest to a specific entity. This meeting is July 24th and 25th and I will provide an update from this meeting in the next newsletter.

Program Committee Report

(Just when you thought you could relax for the summer.....)

Submitted by
Leigh Ann Burns-Naas

Yes, it’s true! SOT 2010 in Salt Lake City is still 19 months away, but it’s time to start planning the programs that the Immunotoxicology Specialty Section will be submitting for the meeting. Our Specialty Section has a terrific track record for submitting multiple, high quality, diverse programs for consideration that will be of value to a broad set of the SOT membership. Key to our success, though is the actual submission of proposals to the ImTox Program Committee and for that we need ALL of our members to start generating those outstanding ideas you know you have. That means YOU!! As you sit by the pool or on the beach with that frosty brew or umbrella drink, dust the cobwebs off those good ideas that have been floating around your head for a while and put together your proposal!! Anyone can submit a proposal, but be advised that SOT mandates that all Chairs and Co-Chairs for all sessions must be members of the SOT.

This year, I’m going to reiterate an appeal that I believe Robert House made a few years back encouraging our younger members to get together and put in some proposals. You are the future of our Specialty Section and there’s no better time than the present to start taking charge! If you aren’t sure about how to put a proposal together, try to connect with an older member who’s put in a few in the past and work with them in a mentorship capacity. Just be careful not refer to us “older members” as “old-timers”! (Gosh, time flies when you’re having fun!) We much prefer, “time-experienced”.

What’s that? You’re not sure if your idea has been presented recently – or ever? Go to the ImTox website at http://www.toxicology.org/ISOT/SS/imunotox/Index.htm and check out our past Immunotoxicology programs. Not sure about what type of proposal you should submit? SOT has a detailed list of the types of sessions online at http://www.toxicology.org/ai/fa/formsapps.asp (it’s under Forms and Applications/On Line Proposals for Annual Meeting Sessions on the main page). A summary of those sessions is presented in this newsletter.

Start with a good idea and then Sell It. Using some recommendations from a past ImTox Program Chair(s), here are some recommendations to get you started.
1. Tie a Hook to Your Line – The Idea/Topic for the Session. Think about a immunotox topic for a session that you have always wanted to see at SOT, or that you think many SOT members – not just the Specialty Section – would be interested in hearing about or that they should know about.

2. Bait Your Hook (And Make it Look Tasty). Devise a title that would catch people’s attention and at least make them want to read the abstract and speakers. Then come up with a potential list of speakers and possible sub-topics they might address. You could even make up their tentative titles. Nothing too flashy…this is science after all, but nothing to make folks snooze either.

3. If the idea is your hook, the title and speakers/sub-topics are your bait, the abstract is really where you can set the hook! Put some meat on the bones of your idea by fleshing out an abstract that describes your idea, including what it is, why it’s important, and what key points will be covered (by your speakers) during the session. (This is where an experienced ImTox member can really help.)

<table>
<thead>
<tr>
<th>Name</th>
<th>Email</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tony Arulanandam</td>
<td><a href="mailto:tarulanandam@shire.com">tarulanandam@shire.com</a></td>
</tr>
<tr>
<td>Leigh Ann Burns-Naas, Chair</td>
<td><a href="mailto:leighann.burns@pfizer.com">leighann.burns@pfizer.com</a></td>
</tr>
<tr>
<td>(Vice-President)</td>
<td></td>
</tr>
<tr>
<td>Jeanine Bussiere (President)</td>
<td><a href="mailto:bussierj@amgen.com">bussierj@amgen.com</a></td>
</tr>
<tr>
<td>George DeGeorge</td>
<td><a href="mailto:degeorge@imbresearch.com">degeorge@imbresearch.com</a></td>
</tr>
<tr>
<td>Nick Filipov</td>
<td><a href="mailto:filipov@cvm.msstate.edu">filipov@cvm.msstate.edu</a></td>
</tr>
<tr>
<td>Vic Johnson</td>
<td><a href="mailto:Vcj6@cdc.gov">Vcj6@cdc.gov</a></td>
</tr>
<tr>
<td>Barb Kaplan</td>
<td><a href="mailto:blkaplan@msu.edu">blkaplan@msu.edu</a></td>
</tr>
<tr>
<td>M. Firoze Khan</td>
<td><a href="mailto:mfkhan@utmb.edu">mfkhan@utmb.edu</a></td>
</tr>
<tr>
<td>Ian Kimber</td>
<td><a href="mailto:Ian.kimber@manchester.ac.uk">Ian.kimber@manchester.ac.uk</a></td>
</tr>
<tr>
<td>Wendy Komacsar</td>
<td><a href="mailto:komocsarwj@lilly.com">komocsarwj@lilly.com</a></td>
</tr>
<tr>
<td>Greg Ladics</td>
<td><a href="mailto:Gregory.s.ladies@usa.dupont.com">Gregory.s.ladies@usa.dupont.com</a></td>
</tr>
<tr>
<td>Michael Lynes</td>
<td><a href="mailto:Michael.lynes@uconn.edu">Michael.lynes@uconn.edu</a></td>
</tr>
<tr>
<td>Ale Manzan</td>
<td><a href="mailto:alemanza@msu.edu">alemanza@msu.edu</a></td>
</tr>
<tr>
<td>Sheung Ng</td>
<td><a href="mailto:ng@env.med.nyu.edu">ng@env.med.nyu.edu</a></td>
</tr>
<tr>
<td>Marc Pallardy</td>
<td><a href="mailto:Marc.pallardy@u-psud.fr">Marc.pallardy@u-psud.fr</a></td>
</tr>
<tr>
<td>Jean Regal (President-Elect)</td>
<td><a href="mailto:jregal@d.umn.edu">jregal@d.umn.edu</a></td>
</tr>
<tr>
<td>Lisa Ryan</td>
<td><a href="mailto:ryanlk@umdnj.edu">ryanlk@umdnj.edu</a></td>
</tr>
<tr>
<td>Jennifer Schlezinger</td>
<td><a href="mailto:jschlezi@bu.edu">jschlezi@bu.edu</a></td>
</tr>
<tr>
<td>Berran Yucesoy</td>
<td><a href="mailto:byucesoy@cdc.gov">byucesoy@cdc.gov</a></td>
</tr>
</tbody>
</table>
4. Reel ‘Em In! Please submit your proposal to leighann.burns@pfizer.com by November 30, 2008. The ImTox Program Committee will meet to review all proposals and may provide some feedback for your consideration (for proposal revision) prior to final ranking of proposals in Baltimore.

There were a lot of submissions and competition for the 2009 annual meeting program; 137 were submitted and 75 were scheduled. On average, there was a 33% acceptance rate on symposia, 49% on workshops, and some were moved to a roundtable session. With that said, we had great success (83.3%) this year with acceptance of program sessions from the ImTox SS! The following sessions have been tentatively accepted for the 48th annual meeting in Baltimore. It was great work by the Chairs and the program committee to put together such quality submissions. This is a great showing for our specialty section and continues to show the interest and effort that this specialty section puts into the annual meeting. Thanks again to everyone for their hard work!

**Accepted Submissions for 2009**

<table>
<thead>
<tr>
<th>Type</th>
<th>Title</th>
<th>Chair and Co-Chair</th>
</tr>
</thead>
<tbody>
<tr>
<td>CE Course</td>
<td>Immunology for Toxicologists</td>
<td>Ian Kimber and Raymond Pieters</td>
</tr>
<tr>
<td>CE Course</td>
<td>Free Radicals for Toxicologists – From the Basics to Inflammation</td>
<td>Lin Mantell and Judith Zelikoff</td>
</tr>
<tr>
<td>(am and pm</td>
<td>and Diseases</td>
<td></td>
</tr>
<tr>
<td>course!)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Workshop</td>
<td>Food Allergy – Basic Mechanisms and Applications to Identifying</td>
<td>MaryJane Selgrade and Susan Laessig</td>
</tr>
<tr>
<td></td>
<td>Risks Associated with Crops</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Workshop</td>
<td>Is Modulation of the Immune System by Perfluoroalkyl Acids a</td>
<td>Jamie DeWitt and Bob Luebke</td>
</tr>
<tr>
<td></td>
<td>Human Health Concern?</td>
<td></td>
</tr>
<tr>
<td>Symposia</td>
<td>Immunomodulation during Complementary and Alternative Medicine</td>
<td>Barbara Kaplan and James Pestka</td>
</tr>
<tr>
<td></td>
<td>(CAM) Therapy: Risks and Benefits</td>
<td></td>
</tr>
<tr>
<td>Symposia</td>
<td>Superantigens, Cytokine Storm, and Toxic Reactions</td>
<td>Ian Kimber and Frank Gerberick</td>
</tr>
<tr>
<td>Symposia</td>
<td>The Good, the Bad and the Ugly of Toxicant-Induced Pulmonary</td>
<td>Lin Mantell and Judy Zelikoff</td>
</tr>
<tr>
<td>Symposia</td>
<td>Immunotoxicology: Transcription Factors, Signal Transduction and</td>
<td>Keiko Nohara and Nancy Kerkvliet</td>
</tr>
<tr>
<td></td>
<td>Epigenetics</td>
<td></td>
</tr>
<tr>
<td>Session Type</td>
<td>Subject Matter</td>
<td>Duration</td>
</tr>
<tr>
<td>----------------------</td>
<td>--------------------------------------------------------------------------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>Symposium</td>
<td>Recent scientific advances</td>
<td>≤ 3 hours</td>
</tr>
<tr>
<td>Workshop</td>
<td>Emphasis on quality presentations of generally accepted, state-of-the-art knowledge in toxicology. Informal, interactive presentations with emphasis on discussion</td>
<td>≤ 3 hours</td>
</tr>
<tr>
<td>Continuing Education</td>
<td>Emphasis on quality presentations of generally accepted, state-of-the-art knowledge in toxicology</td>
<td>4 hr Sunrise, 1 hr</td>
</tr>
<tr>
<td>Roundtable</td>
<td>Controversial subjects</td>
<td>1.5 hr</td>
</tr>
<tr>
<td>Historical Highlight</td>
<td>The selected topic should be broad based, include the contributions of multiple laboratories and feature a review of a historical body of science that has impacted the field of toxicology. The title should be descriptive of the advancement that has been achieved and/or the impact of the advancement</td>
<td>1.5 hr</td>
</tr>
<tr>
<td>Informational Session</td>
<td>Not based on the outcome of scientific research. Should address informational needs of members on topics such as Career Development, General Information, and Planned Scientific Activities</td>
<td>1.5 or 2.75 hr (need to explain extended time need)</td>
</tr>
</tbody>
</table>
Greetings fellow students and post-docs! We hope all of you are enjoying the summer.

Not too much has changed since the last newsletter so this serves as a reminder/update on a few things. Please continue to watch for information about our meeting place in upcoming communications from the ImTox SS as the national meeting approaches. For those of you looking for the most up to date information related to SOT please visit the SOT website for students and postdocs: http://www.toxicology.org/ISOT/SS/imtox/stu_info.asp.

Please keep in mind that the deadline for submitting the ‘Best Presentation by a Graduate Student/Postdoctoral Fellow’ Award is February 1, 2009. Application for this award should include a complete written version (all graphs and tables) of an immunotoxicology presentation to be made at the 2009 SOT annual meeting accompanied by a nomination letter from your advisor. Only electronic submissions will be accepted. Winners will receive a plaque and cash award, as well as the recognition during the ImTox SS reception at the annual meeting! Take some time to let your hard work be rewarded! Please forward your submissions to Dr. Rodney Dietert (rrd1@cornell.edu).

If you missed the ImTox SS student/postdoc mixer at the Tap House Grill at Seattle, we will have a similar opportunity to socialize with one another at the meeting in Baltimore. We are always expecting to see more of you in future mixers. Should you have any suggestion about other type of events, please also feel free to contact Stacey (sanderson4@cdc.gov) or Haitian (luhaitia@msu.edu).

Another great way of making new contacts for students is to get involved in the ImTox SS committees. Committees that are open to student members include the Awards, Communications, Program, and Regulatory committees. Descriptions of these committees are available on the ImTox SS website. Student participation in these committees is greatly encouraged. If you are interested, please sign up during the ImTox SS reception at the annual meeting, or send your inquiry directly to the chairmen of committees.

The term for Dr. Stacey Anderson as the ImTox SS postdoctoral representative will end in March 2009. We are now looking for a new postdoctoral representative to replace her. For those interested in this position, please send your CV and a nomination letter from your advisor to Dr. Jeanine Bussiere (bussierj@amgen.com). You would also need to verify with your advisor that he/she is willing to fund your travel to SOT for the next two years. Please do not hesitate to contact Stacey or Haitian for more information about this position. Your term would run from March 2009 to March 2011. You would serve as the postdoctoral voice on the ImTox SS and it is a great opportunity to broaden your professional network!
IMMUNOTOXICITY EVALUATION: FROM THE BENCH TO THE CLINIC

17th Summerschool in Immunotoxicology

Grand Hotel, Avignon (France), 22-24 September 2008
Announcements

17th Summerschool in Immunotoxicology

Grand Hotel, Avignon (France), 22-24 September 2008

IMMUNOTOXICITY EVALUATION:
FROM THE BENCH TO THE CLINIC

Monday 22 September
10:00  Start of registration and welcome coffee
12:00  Opening lunch
13:45  Welcome to participants
14:00  Immunotoxicity evaluation: the needed transition from animal to man. K.Hastings (Sanofi-Aventis, USA)
14:45  In vitro immunotoxicity: current situation and perspectives. M.Pollardy (School of Pharmacy, Paris University, France)
15:30  Coffee break
16:00  Predictability and limitations of animal immunotoxicity studies. B.Molinier (Sanofi-Aventis, France)
16:45  Summerschool in Immunotoxicology Annual PhD Award
17:30  Social event
20:00  Dinner

Tuesday 23 September
9:00  Safety immunopharmacology. J.Descotes (Poison Center, Lyon, France)
9:45  Practical transition of immunotoxicity evaluation from animal to man. J.Piccotti (Schering-Plough, USA)
10:30  Coffee break
11:00  Clinical immunological endpoints for use in human immunotoxicity studies. A.Marchant (Institute of Clinical Immunology, Brussels, Belgium)
11:45  Recommendations for a better identification of infectious complications in clinical trials. M.E.Falagas (Alfa Institute of Medical Sciences, Athens, Greece)
12:30  Lunch
13:45  Immunotoxicity of anti-TNFα drugs: from animals to man. A.Gouraud (Poison Center and Pharmacovigilance, University Hospitals, Lyon, France)
14:30  Case study: H.Lebrèc (Amgen, USA)
15:15  Case study: E.Evans (Schering-Plough, USA)
16:00  Coffee Break
16:15  Social Event and Gala Dinner

Wednesday 24 September
9:30  Immunotoxicity evaluation from animal to man: a regulatory perspective. C.Booker (FDA, USA)
10:15  Immunotoxicity evaluation in early clinical development: an industry perspective. I.Gourley (Wyeth, USA)
11:00  General discussion
12:00  Concluding remarks and closure of summerschool
12:15  Farewell lunch

Visit our web site at http://www.school-immunotoxicology.org/
Announcements

FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH

Cytokine Release: What Does It Mean?
October 20, 2008
FDA White Oak Campus, CSU Room 2047

9:00 – 9:15 am  Opening Remarks
Carmen Booker, PhD
Food and Drug Administration
CDER PTCC Immunotoxicology Subcommittee Chair

9:15 – 10:15 am  Plenary Lecture
Cytokine Release Syndrome in a Phase One Clinical Trial
Sir Gordon Duff
Florey Professor of Molecular Medicine, University of Sheffield.
Chairman, UK Commission on Human Medicines

10:15 – 10:30 am  Break

10:30 – 11:30 am  New Developments in the Nonclinical Assessment of Cytokine Release
Tom Kawabata, PhD, Pfizer Global Research and Development
Peter Bugelski, PhD, Johnson & Johnson
Wendy Komocsar, Eli Lilly & Company

11:30 am – 12:30 pm  Lunch

12:30 – 1:30 pm  The Utilization of Current Nonclinical Data to Predict Cytokine Release Potential
Margot O’Toole, PhD, Wyeth Research
Carmen Booker, PhD, Food and Drug Administration
L. Peyton Myers, PhD, Food and Drug Administration

1:30 – 1:45 pm  Break

1:45 – 2:45 pm  The Impact of Possible Cytokine Release on Clinical Trial Design
Steven W. Martin, PhD, Pfizer Global Research and Development
Patricia Keegan, MD, Food and Drug Administration

2:45 – 3:00 pm  Break

3:00 – 4:00 pm  Panel Discussion

4:00 – 4:30 pm  Optional Tour of FDA Facility
### Announcements

**Cytokine Release: What Does It Mean?**

**US Food and Drug Administration**

**Silver Spring, MD**

**Monday, October 20, 2008**

**Registration Form**

<table>
<thead>
<tr>
<th>Personal Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Name:</td>
</tr>
<tr>
<td>Company:</td>
</tr>
<tr>
<td>Address:</td>
</tr>
<tr>
<td>City:</td>
</tr>
<tr>
<td>State/Province:</td>
</tr>
<tr>
<td>Zip/Postal Code:</td>
</tr>
<tr>
<td>Country:</td>
</tr>
<tr>
<td>Email:</td>
</tr>
<tr>
<td>Phone:</td>
</tr>
</tbody>
</table>

**Registration Fees**

There is no registration fee.

**Location Information**

This conference will be held at the US FDA White Oak Campus in Silver Spring, MD.

10903 New Hampshire Ave  
Silver Spring, MD  20903

**Registration Information**

**DEADLINE: Wed, September 17, 2008.**

Registration for non-FDA employees is being **limited to the first 100 registrants.**

To complete your registration, **EMAIL** this information to:

Carmen.Booker@fda.hhs.gov

Alternatively, you can also **PRINT** and **MAIL/FAX** your registration to:

**Carmen Booker, Ph.D.**  
Chair, Immunotoxicology Subcommittee  
US Food and Drug Administration  
CDER/OND/ODE III  
Division of Dermatology and Dental Products  
10903 New Hampshire Ave  
Silver Spring, MD  20903  
(301) 796-0853 (Voice)  
(301) 796-9895 (Fax)
Announcements

Naturally Occurring Infections in Nonhuman Primates and Immunotoxicity Implications

Date and Time:
Wednesday, October 22nd
8:30 AM - 4:30 PM

Location:
Silver Spring, MD
(specific location to be determined)

Targeted Audience:
Lab animal vets, pathologists, toxicologists, regulatory scientists and epidemiologists

Workshop Goal and Objectives:
The primary goal of this workshop is to provide a multidisciplinary forum to advance our understanding of the implications of naturally occurring infections in NHPs. The specific objectives for this workshop are information sharing, identification of data gaps, and discussion of key topics.

Workshop Format:
The morning will consist of topical presentations on naturally occurring infections in NHPS, including a number of 'case studies'. The afternoon will be devoted to a series of 'discussion questions'.

Workshop Organizers:
Members of the Immunotoxicology Technical Committee (ITC) from the ILSI Health and Environmental Sciences Institute (HESI).

Primary Contact:
This is an open workshop; but space is limited.

For additional information, please contact:
Dr. Raegan O'Lone
Scientific Program Manager for the ITC
Email: ROLone@hesiglobal.org.
Phone: 202-659-3306
Naturally Occurring Infections in Nonhuman Primates and Immunotoxicity Implications

Date and Time: Wednesday, October 22nd  
8:30 AM – 4:30 PM

Location: Silver Spring, MD
Organizers: Members of the Immunotoxicology Technical Committee (ITC) from the ILSI Health and Environmental Sciences Institute (HESI)

Tentative Agenda:

8:30 - 8:45 I.a. Introduction. Ellen Evans (Schering-Plough; ITC member)  
There is increased concern that naturally occurring infectious disease may complicate interpretation of study findings in toxicology assessments. These concerns are heightened with the development of various types of immunomodulatory agents and the use of NHP from different sources. Therefore, it is critical for key stakeholders (toxicologists, lab animal veterinarians and regulatory scientists) to discuss potential types of infections, their characteristics and how they may impact the interpretation of toxicology studies. Moreover, the potential use and misuse of infections and immune responses to infections to assess the immunosuppression potential needs to be more fully discussed.

8:45 - 9:00 I.b. Introduction. FDA scientist (to be determined)

9:00 - 9:30 II. Overview of known NHP pathogens with potential to affect colonies used for toxicity testing. Vito Sasseville (Bristol-Myers Squibb)  
This overview will include a discussion of primary and opportunistic viruses, bacteria, and parasites that have had the most profound impact on the interpretation of drug safety studies. In particular, SIV and SRV primary inflammatory disease and associated opportunistic diseases, measles, and Plasmodium spp will be discussed.

9:30 – 10:00 III. Overview of immunosuppressive viruses of NHP’s. Nick Lerche (U.C. Davis)  
The emphasis will be on the history, biology, and impact of immunosuppressive viruses (SIV/SRV) on health of animals and the conduct of toxicology studies. Some discussion on primary clinical and subclinical disease and increased susceptibility to secondary infection will be included; specific opportunistic/secondary infections will be discussed by other presenters.
10:00 – 10:30 IV. Latent viruses and potential for use in monitoring immunosuppression. Joe Simmons (Charles River Laboratories)

A discussion of the immunology associated with latency, host resistance, and recrudescence with emphasis on Herpes viruses. The SPF issue will be discussed, as well as use of latent viruses to assess immunosuppression.

10:30 - 10:45 BREAK

10:45 – 11:15 V. Clinical veterinarian’s perspective of NHP infection in a toxicology setting. Chris Petursson (Bristol-Myers Squibb)

Organisms which are be part of normal flora or subclinical in healthy monkeys may cause clinical disease during a toxicity study. The challenges in data interpretation and/or opportunities to utilize information as a natural “host resistance” assay; mechanisms of host resistance (e.g. what disruptions in host resistance might result in opportunistic infections with a given organism) will be discussed. This overview will include perspectives on husbandry practices, diagnosis, treatment, and prescreening.

11:15 – 12:00 VI. Case studies (Lymphoma, malaria, measles). David Hutto (Biogen Idec)

12:00 - 12:30 VII. Case study (Focus on a small molecule and impact of opportunistic bacterial infection). Karen Price (Bristol-Myers Squibb; ITC member)

12:30 - 1:15 LUNCH

1:15 - 4:15 FACILITATED DISCUSSION

1:15 – 2:00 VIII. Discussion Session #1. Ken Olivier (GlaxoSmithKline) / Joe Simmons (CRL)

Is it feasible to have “cleaner” monkeys for studies? While there are routine screens used for most communicable diseases in NHP that can be transmitted to humans, there is a need to screen for pathogens more specific to NHPs, and possibly latent, that may recrudesce during toxicology studies and confound data interpretation. What are some prophylactic antiparasitics and how good are they in minimizing adverse events (e.g. diarrhea, malaria) related to increased incidences of infection during the course of a study? In addition to typical NHP screens protecting human lab animal workers, should we be screening for other viruses, fungi, bacteria and/or parasites? Is it better to have a certain background incidence of naturally occurring organisms in order to demonstrate immunosuppression, or is it preferable to start studies with the cleanest monkeys possible? What does SPF mean in a toxicology setting? Who are some points of contact (experts) to educate those in need?
2:00 – 2:45 IX. Discussion Session #2. Chris Petursson (BMS) / FDA scientist (to be determined)

Is it appropriate to treat monkeys which develop infections or diarrhea on toxicity studies with antiparasitics, antibiotics, etc. or is there a danger of “masking” an immunosuppressive effect? How do we interpret the outcome of animals which are treated for infection vs. those which are not?

2:45 – 3:30 X. Discussion Session #3. Karen Price (BMS) / FDA scientist (to be determined)

What are the regulatory implications when infection is observed as an expected pharmacologic effect? How should data be interpreted within a study and across studies with the same drug where infections are seen in some studies and not in others? What additional data regarding is needed to aid in the interpretation of the toxicology findings (e.g. identification of a specific organism, relationship between histopathological finding and infection)?

3:30 – 4:15 XI. Discussion Session #4. David Hutto (Biogen Idec) / Jeannine Bussiere (Amgen; ITC member) / FDA scientist (to be determined)

Should we try to use latent viral status to assess immunosuppression during the course of a study? If so, which ones and what are the testing requirements and limitations (e.g. whole cells, banked serum, PCR vs. Ab titers, etc.)? What are the limitations and pitfalls of this approach? Are these the best ways to assess immunomodulation / immunotoxicity, or are there other currently employed methods which might be better such as functional assays or host resistance studies with a control in the amount of inoculum (bacteria, virus, fungus, or tumor) rather than depending on spontaneous background distribution? What can we learn from studies conducted on immune responses to latent viral infections in humans and will the NHP findings translate to humans?'

4:15 – 4:30 XII. Closing Remarks; Next Steps. Tom Kawabata (Pfizer; ITC member) / Helen Haggerty (BMS; ITC member)
STAFF TOXICOLOGIST
WIL Research Laboratories, LLC
Ashland, Ohio

If you are an accomplished scientist with excellent interpersonal skills, an entrepreneurial bent, and enjoy a brisk turnover of new and interesting scientific projects, you should investigate the opportunities at WIL Research Laboratories, LLC. The diversity of this position provides the successful candidate with a personal growth opportunity covering science, project management and business acumen, unique in the contract research organization (CRO) industry.

WIL Research Laboratories, LLC is a successful, mid-size, interdisciplinary, non-clinical CRO, providing toxicology and related services to pharmaceutical, biotechnology, chemical, veterinary and food product industries. WIL is seeking a qualified Staff Toxicologist. As such, the successful candidate will be the responsible staff scientist and project manager for toxicology studies. This involves communication with scientific and regulatory sponsor representatives and consultants, study costing, proposal and protocol preparation, study implementation and interpretation of the results obtained. The candidate would be expected to remain current with technical advances and regulatory requirements in the applicable area of expertise.

The successful candidate will be expected to have a PhD (or BS or MS with significant applicable experience) in Toxicology, Pharmacology, Cellular Biology, Physiology, Microbiology, Immunology or other closely related discipline. ABT certification and experience in GLP environment would be desirable, but not required. General toxicology studies range from single-dose studies through 2-year bioassays, using a unique variety of in vivo test models, routes of administration, and study designs. The studies integrate pharmacodynamic observations with a variety of different disciplines such as laboratory animal medicine, clinical pathology, anatomic pathology, toxicokinetics and analytical chemistry.

Salary will be commensurate with experience and level of accomplishment. WIL is located in North Central Ohio, with easy access to Cleveland, Columbus and a variety of cultural and recreational activities. For consideration, download an employment application from our website (www.wilresearch.com) and mail or fax the completed application, along with a resumé, to WIL Research Laboratories, LLC, Attn: Human Resources, 1407 George Road, Ashland OH 44805. Fax: (419) 289-3650.
RESEARCH SCIENTIST

IMMUNOLOGY/IMMUNOTOXICOLOGY

WIL Research Laboratories, LLC

Ashland, Ohio

If you are an accomplished scientist with excellent interpersonal skills, an entrepreneurial bent, and enjoy a brisk turnover of new and interesting scientific projects, you should investigate the opportunities at WIL Research Laboratories, LLC. The diversity of this position provides the successful candidate with a personal growth opportunity covering science, project management and business acumen, unique in the contract research organization (CRO) industry.

WIL Research Laboratories, LLC is a successful, mid-size, interdisciplinary, non-clinical CRO, providing toxicology and related services to pharmaceutical, biotechnology, chemical, veterinary and food product industries. WIL is seeking a qualified immunologist and/or immunotoxicologist who will be responsible for the evaluation, development, optimization, validation and implementation of flow cytometry procedures and immunoassays in a GLP environment to support regulatory requirements. As such, the successful candidate will have overall responsibility for communication with scientific and regulatory sponsor representatives, proposal and protocol preparation, study design and costing, and data interpretation. A strong background and expertise in immunoassay methodology (ELISA, ECLA, FIA, RIA), immunology or immunotoxicology, flow cytometry techniques and tissue culture is essential. It is expected that the individual can work independently with general direction from a supervisor to achieve departmental goals and objectives. Must be able to analyze and exercise independent judgment in troubleshooting and optimizing assay development and performance.

The successful candidate will be expected to have a PhD in a discipline of Immunology, Microbiology, Pharmacology, Toxicology or a related field, with training in Immunotoxicology. A minimum of 2 years specific research experience is preferred and experience in a GLP-compliant environment is desirable, but not required. Salary will be commensurate with experience and level of accomplishment. WIL is located in North Central Ohio, with easy access to Cleveland, Columbus and a variety of cultural and recreational activities. For consideration, download an employment application from our website (www.wilresearch.com) and mail or fax the completed application, along with a resumé, to WIL Research Laboratories, LLC, Attn: Human Resources, 1407 George Road, Ashland OH 44805. Fax: (419) 289-3650.
RESEARCH POSITION
U.S. Environmental Protection Agency
National health and Environmental Effects Research Laboratory
Immunotoxicology Branch

The Immunotoxicology Branch, U.S. Environmental Protection Agency in Research Triangle Park, NC is anticipating an opening for a principal investigator at the GS-12/13/14 level. The initial project will apply molecular and high throughput technologies to develop new approaches for identification of chemical sensitizer and more generally consider the issue of Toxicity Testing in the 21st Century (http://www.nap.edu/openbook.php?record_id=11970&page=56), in the context of all aspects of immunotoxicology. In the longer term the incumbent is expected to develop an immunotoxicology research program that is scientifically sound and provides information that helps to solve Agency problems. This requires keeping abreast of the latest science as well as the Agency’s issues and collaborating with scientists across the Office of Research and Development to incorporate their work in a larger multidisciplinary approach to highly visible Agency problems. For more information on the organization see http://www.epa.gov/nheerl/etd/

Qualifications: An immunologist/immunotoxicologist with capabilities to bring molecular technologies/systems biology approaches to bear on the array of immunotoxicity problems and the willingness to think across levels of biologic organization from molecular effects to disease outcomes and to relate animal data to human outcomes. The current staff is well established and able to provide many of the necessary phenotypic hooks

For more information contact:

MaryJane Selgrade, Ph.D.
Chief, Immunotoxicology Branch
MD-B143-01
US EPA
Research Triangle Park, NC 27711
Phone: 919-541-1821
FAX: 919-541-4284
Email: Selgrade.maryjane@epa.gov
Recent Immunotoxicology Publications

Compiled by Haley Neff-LaFord.

ANYTIME you have a new publication to report, please send it to the coordinator, Haley Neff-LaFord:
hnlaford@seagen.com

Asthma, Allergy, Autoimmunity & Hypersensitivity


Effects: Compounds


General Immunotoxicology


**Methods**


Reviews, Workshops & Book Chapters


